Results of the first study on intraperitoneal virotherapy employing a recombinant vaccinia virus genetically engineered to selectively replicate in and destroy cancer cells

Introduction: GL-ONC1 constitutes a recombinant Vaccinia virus genetically engineered to selectively replicate in and destroy cancer cells. Since GL-ONC1 encodes state-of-the-art marker genes, features of its tumor cell colonization, in-patient replication, and oncolysis can be tracked excellently. We here report our data obtained in patients with peritoneal carcinomatosis (PC) who have been recruited to our ongoing phase I/II virotherapy study (NCT01443260). Methods: GL-ONC1 is administered intraperitoneally up to 4 times under a standard 3+3 dose escalation design. Virological data and anti-tumor activities ar…